Company Listing
eFFECTOR Therapeutics

eFFECTOR is developing a novel class of small molecule drugs to selectively regulate translation (protein synthesis) with an initial emphasis on cancer. Kevan Shokat, ex-Intellikine (a portfolio company that Abingworth exited successfully in 2012), is one of the scientific founders.

BACK
Location
San Diego, California
CEO
Steve Worland
Abingworth Partner
Ken Haas
Website Address

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

eFFECTOR is developing a novel class of small molecule drugs to selectively regulate translation (protein synthesis) with an initial emphasis on cancer. Kevan Shokat, ex-Intellikine (a portfolio company that Abingworth exited successfully in 2012), is one of the scientific founders.

Location
San Diego, California
CEO
Steve Worland
Abingworth Partner
Ken Haas
Website Address
BACK
 
Copyright Abingworth 2017